Glaukos has a twelve month low of $77.91 and ... and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery ...

Glaukos Corporation's shares have fallen 21% in the last 10 months due to sustained negative profitability. Read why GKOS ...

Strong Product Demand: Glaukos' rising share price is largely driven by the success of its flagship product, iStent. The company delivered robust performance during 2024 and maintains a favorable ...

Corebridge Financial Inc. decreased its position in Glaukos Co. (NYSE:GKOS – Free Report) by 7.2% in the fourth quarter, ...

Learn more about whether Glaukos Corporation or Globus Medical, Inc. is a better investment based on AAII's A+ Investor ...

Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Strong Product Demand: Glaukos' rising share price is largely driven by the success of its flagship product, iStent. The company delivered robust performance during 2024 and maintains a favorable ...